Return to homepagePandemic Pact

Discovery and Translational Sciences

Grant number: INV-005948

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2020

  • Known Financial Commitments (USD)

    $39,600

  • Funder

    Gates Foundation

  • Principal Investigator

    N/A

  • Research Location

    India

  • Lead Research Institution

    Indian Institute of Science

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

to develop subunit-based immunogens to the newly emerged Coronavirus as candidate vaccines

Publicationslinked via Europe PMC

Last Updated:7 days ago

View all publications at Europe PMC

Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants.

Identification of diphenylurea derivatives as novel endocytosis inhibitors that demonstrate broad-spectrum activity against SARS-CoV-2 and influenza A virus both in vitro and in vivo.

Biophysical Correlates of Enhanced Immunogenicity of a Stabilized Variant of the Receptor Binding Domain of SARS-CoV-2.

Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern.

A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein.

Mechanistic insights into global suppressors of protein folding defects.

Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens.

Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice.

Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative.